Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants

Immunization with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has greatly reduced coronavirus disease 2019 (COVID-19)-related deaths and hospitalizations, but waning immunity and the emergence of variants capable of immune escape indicate the need for novel SARS-CoV-2 vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Beavis, Ashley C., Li, Zhuo, Briggs, Kelsey, Huertas-Díaz, María Cristina, Wrobel, Elizabeth R., Najera, Maria, An, Dong, Orr-Burks, Nichole, Murray, Jackelyn, Patil, Preetish, Huang, Jiachen, Mousa, Jarrod, Hao, Linhui, Hsiang, Tien-Ying, Gale, Michael, Harvey, Stephen B., Tompkins, S. Mark, Hogan, Robert Jeffrey, Lafontaine, Eric R., Jin, Hong, He, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196109/
https://www.ncbi.nlm.nih.gov/pubmed/35702147
http://dx.doi.org/10.1101/2022.06.07.495215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196109/
https://www.ncbi.nlm.nih.gov/pubmed/35702147
http://dx.doi.org/10.1101/2022.06.07.495215

Ejemplares similares